The investigators plan to enroll women with PE prospectively to evaluate incremental cardiovascular risk in those who have PE with severe features. This study includes detailed echocardiographic evaluation at several time points. With the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. This opens the door to earlier detection, treatment and improved cardiovascular outcomes.
Preeclampsia (PE) is a multi-system progressive disorder affecting up to 8% of pregnancies. Epidemiologic studies have shown a significant association between PE and future cardiovascular disease (CVD) in women. Despite recognition of this relationship, there are no good markers to help determine which women are at highest risk, in particular as this relates to long-term cardiovascular risk, the number one cause of mortality in U.S. born women. As such, the study of PE and cardiovascular outcomes, in particular to identify early markers for the development of late CVD, provide insight into critical opportunities for early treatment and modification of disease trajectory in women. The investigators plan to enroll women with PE prospectively to evaluate incremental cardiovascular risk in those who have PE with severe features. This study includes detailed echocardiographic evaluation at several time points. With the current proposal, the investigators aim to collect blood to evaluate several biomarkers to determine if there is a correlation with short and medium-term cardiovascular risk. This opens the door to earlier detection, treatment and improved cardiovascular outcomes. The investigators hypothesize that preeclampsia with severe features confers a much higher risk of cardiovascular impairment compared to milder form of preeclampsia and healthy controls. If the hypothesis proves correct, these findings may change clinical practice by warranting routine echocardiogram for these patients for early recognition, intervention and treatment of cardiac dysfunction.
Study Type
OBSERVATIONAL
Enrollment
27
Serial echocardiograms will be done on all patients pre-delivery, and at 3-6 months
Serial blood draws at same time points as echocardiograms for biomarker levels
The Ohio State University
Columbus, Ohio, United States
Cardiac dysfunction
The following parameters will be measured to assess cardiac dysfunction: 1. LV Size/function 1. Biplane Method of Disks LVEF (a4C and 2C views for EDV and ESV) 2. LV Fractional shortening- Septal thickness and PW thickness 3. LV Strain- Basal longitudinal, Mid LV longitudinal, Apical LV longitudinal and Global LV longitudinal strain 4. 3D LV EF 5. Tei index 6. Analysis of LV diastolic function- Mitral E wave, Mitral A wave, Mitral e', Mitral E/e', Mitral E/A and Mitral Decel time 2. LA volume 3. RA volume 4. IVC size/compressibility with inspiration 5. RV size/function 1. RV length 2. RV basal width 3. RV FAC % 4. TAPSE 5. S' 6. Tei index 7. TR velocity 8. RVSP 9. TAPSE 10. Longitudinal strain- Basal Longi, Basal longitudinal, Mid LV longitudinal, Apical LV longitudinal and Global LV longitudinal strain 6. Basic valve assessment
Time frame: From delivery up to 3-6 months postpartum
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.